Cryolife Inc (CRY) Post-Earnings Boom Entices Options Players

Cryolife Inc (CRY) call options are in high demand, as the stock zooms higher on earnings

Jul 26, 2016 at 2:04 PM
facebook twitter linkedin

Like these four stocks, Cryolife Inc (NYSE:CRY) is capitalizing on a strong earnings report. Specifically, the healthcare firm swung to a sharper-than-expected second-quarter profit, sending the stock 16.6% higher to $14.01 -- and to a seven-year high of $14.18. Meanwhile, CRY has elicited a powerful response from the analyst and options crowds alike.

For starters, the stock is also being boosted by a pair of price-target hikes. Specifically, Ladenburg Thalmann raised its target price to $13.50 from $12, while Canaccord Genuity lifted its outlook to $17.50 from $14.50 -- territory not charted by CRY since mid-2002.

Meanwhile, call options are flying at 33 times the usual intraday rate (albeit on relatively low absolute volume). In the lead is the out-of-the-money October 15 call, which is likely seeing buy-to-open activity. In other words, option bulls are banking on CRY toppling $15 -- and hitting fresh multi-year highs -- by October expiration, at the close on Friday, Oct. 21.

Meanwhile, one group of previously bearish traders may be thanking their lucky stars. Specifically, short interest plunged nearly 30% in the most recent reporting period, suggesting plenty of skeptics hit the exits in the nick of time. With today's bullish gap, Cryolife Inc (NYSE:CRY) now sports a gaudy year-to-date advance of 30%.

Sign up now for Schaeffer's Market Recap to get all the day's big stock movers, must-know technical levels, and top economic stories straight to your inbox.


If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Master Portfolio Trial


Special Offers from Schaeffer's Trading Partners